This product review is on the use of tolvaptan in the management of autosomal dominant polycystic kidney disease.
This review discusses the evidence in support of the use of this approach, disease burden, the drugs’ pharmacology including mechanism of action, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Professor Carol Pollock, an academic nephrologist and renal transplant physician with over 320 publications in basic research and clinical medicine.
Please login below to download this issue (PDF)